Mountain Capital Investment Advisors Inc trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 13.8% in the 4th quarter, Holdings Channel.com reports. The fund owned 2,164 shares of the life sciences company’s stock after selling 346 shares during the quarter. Mountain Capital Investment Advisors Inc’s holdings in Illumina were worth $806,000 as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. OLD Second National Bank of Aurora raised its holdings in shares of Illumina by 437.5% during the third quarter. OLD Second National Bank of Aurora now owns 86 shares of the life sciences company’s stock worth $27,000 after acquiring an additional 70 shares in the last quarter. Westside Investment Management Inc. purchased a new stake in shares of Illumina during the third quarter worth $30,000. Newfound Research LLC purchased a new stake in shares of Illumina during the third quarter worth $31,000. Carroll Financial Associates Inc. purchased a new stake in shares of Illumina during the fourth quarter worth $31,000. Finally, Price Wealth LLC raised its holdings in shares of Illumina by 626.7% during the third quarter. Price Wealth LLC now owns 109 shares of the life sciences company’s stock worth $34,000 after acquiring an additional 94 shares in the last quarter. Institutional investors and hedge funds own 78.43% of the company’s stock.
Several research firms have commented on ILMN. SVB Leerink increased their target price on shares of Illumina from $325.00 to $360.00 and gave the stock an “outperform” rating in a research report on Monday, December 7th. UBS Group downgraded shares of Illumina from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $390.00 to $285.00 in a research report on Tuesday, September 22nd. Guggenheim downgraded shares of Illumina from a “buy” rating to a “neutral” rating in a research report on Tuesday, October 13th. Piper Sandler raised shares of Illumina from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $340.00 to $415.00 in a research report on Tuesday, December 22nd. Finally, TheStreet raised shares of Illumina from a “c+” rating to a “b-” rating in a research report on Tuesday, December 22nd. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $334.14.
Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, October 29th. The life sciences company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Illumina had a return on equity of 15.93% and a net margin of 19.70%. The business had revenue of $794.00 million for the quarter, compared to the consensus estimate of $713.97 million. During the same period last year, the business earned $1.93 earnings per share. The firm’s revenue for the quarter was down 12.5% compared to the same quarter last year. On average, equities research analysts anticipate that Illumina, Inc. will post 4.31 EPS for the current year.
In other Illumina news, SVP Aimee L. Hoyt sold 215 shares of the firm’s stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $310.10, for a total transaction of $66,671.50. Following the completion of the transaction, the senior vice president now owns 3,313 shares in the company, valued at $1,027,361.30. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Aimee L. Hoyt sold 271 shares of the firm’s stock in a transaction dated Monday, January 11th. The stock was sold at an average price of $379.65, for a total transaction of $102,885.15. Following the transaction, the senior vice president now owns 2,630 shares of the company’s stock, valued at approximately $998,479.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,864 shares of company stock worth $11,405,520. 0.38% of the stock is owned by company insiders.
Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.